Skip to main content
Top
Published in: Clinical and Experimental Medicine 7/2023

22-09-2023 | Review

The mechanisms and therapeutic potential of long noncoding RNA NEAT1 in fibrosis

Author: Xiaoying Jiang

Published in: Clinical and Experimental Medicine | Issue 7/2023

Login to get access

Abstract

Fibrosis is the excess deposition of extracellular matrix involved in the pathogenesis of chronic diseases and finally leads to the disruption of tissue architecture and failure of organ function. Long noncoding RNAs (lncRNAs) are a class of RNAs with lengths greater than 200 nucleotides and do not code proteins, which regulate gene expression at multiple levels. Nuclear-enriched abundant transcript 1 (NEAT1) is a long noncoding RNA that is widely expressed in mammalian cells and known as essential architectural scaffold for the formation of paraspeckles. Recently, the accumulating studies demonstrated that lncRNA NEAT1 was remarkable upregulated in the development of fibrosis in different organs, such as liver fibrosis, renal fibrosis, cardiac fibrosis, and lung fibrosis. More importantly, knockdown of NEAT1 remarkably alleviated fibrosis in vitro and in vivo. In this review, we summarized current studies of NEAT1 in fibrosis and hopefully aid in a better understanding of the mechanisms of fibrosis and the potential of NEAT1 as novel therapeutic target for fibrosis.
Literature
1.
go back to reference Xiang Z, Liqing Y, Qingqing Y, Qiang H, Hongbo C. Retard or exacerbate: role of long non-coding RNA growth arrest-specific 5 in the fibrosis. Cytokine Growth Factor Rev. 2022;67:89–104.PubMed Xiang Z, Liqing Y, Qingqing Y, Qiang H, Hongbo C. Retard or exacerbate: role of long non-coding RNA growth arrest-specific 5 in the fibrosis. Cytokine Growth Factor Rev. 2022;67:89–104.PubMed
2.
go back to reference Jiang X, Ning Q. The mechanism of lncRNA H19 in fibrosis and its potential as novel therapeutic target. Mech Ageing Dev. 2020;188: 111243.PubMed Jiang X, Ning Q. The mechanism of lncRNA H19 in fibrosis and its potential as novel therapeutic target. Mech Ageing Dev. 2020;188: 111243.PubMed
3.
go back to reference Gu YY, Dou JY, Huang XR, Liu XS, Lan HY. Transforming growth factor-β and long non-coding RNA in renal inflammation and fibrosis. Front Physiol. 2021;12: 684236.PubMedCentralPubMed Gu YY, Dou JY, Huang XR, Liu XS, Lan HY. Transforming growth factor-β and long non-coding RNA in renal inflammation and fibrosis. Front Physiol. 2021;12: 684236.PubMedCentralPubMed
4.
go back to reference Jusic A, Thomas PB, Wettinger SB, et al. Noncoding RNAs in age-related cardiovascular diseases. Ageing Res Rev. 2022;77: 101610.PubMed Jusic A, Thomas PB, Wettinger SB, et al. Noncoding RNAs in age-related cardiovascular diseases. Ageing Res Rev. 2022;77: 101610.PubMed
5.
go back to reference Ghafouri-Fard S, Abak A, Talebi SF, et al. Role of miRNA and lncRNAs in organ fibrosis and aging. Biomed Pharmacother. 2021;143: 112132.PubMed Ghafouri-Fard S, Abak A, Talebi SF, et al. Role of miRNA and lncRNAs in organ fibrosis and aging. Biomed Pharmacother. 2021;143: 112132.PubMed
6.
go back to reference Karimi B, Dehghani Firoozabadi A, Peymani M, Ghaedi K. Circulating long noncoding RNAs as novel bio-tools: Focus on autoimmune diseases. Hum Immunol. 2022;83(8–9):618–27.PubMed Karimi B, Dehghani Firoozabadi A, Peymani M, Ghaedi K. Circulating long noncoding RNAs as novel bio-tools: Focus on autoimmune diseases. Hum Immunol. 2022;83(8–9):618–27.PubMed
7.
go back to reference Castro-Oropeza R, Piña-Sánchez P. Epigenetic and transcriptomic regulation landscape in HPV+ cancers: biological and clinical implications. Front Genet. 2022;13: 886613.PubMedCentralPubMed Castro-Oropeza R, Piña-Sánchez P. Epigenetic and transcriptomic regulation landscape in HPV+ cancers: biological and clinical implications. Front Genet. 2022;13: 886613.PubMedCentralPubMed
8.
go back to reference Abrishamdar M, Jalali MS, Rashno M. MALAT1 lncRNA and Parkinson’s disease: the role in the pathophysiology and significance for diagnostic and therapeutic approaches. Mol Neurobiol. 2022;59(9):5253–62.PubMed Abrishamdar M, Jalali MS, Rashno M. MALAT1 lncRNA and Parkinson’s disease: the role in the pathophysiology and significance for diagnostic and therapeutic approaches. Mol Neurobiol. 2022;59(9):5253–62.PubMed
9.
go back to reference Smith NE, Spencer-Merris P, Fox AH, Petersen J, Michael MZ. the long and the short of It: NEAT1 and cancer cell metabolism. Cancers (Basel). 2022;14(18):4388.PubMed Smith NE, Spencer-Merris P, Fox AH, Petersen J, Michael MZ. the long and the short of It: NEAT1 and cancer cell metabolism. Cancers (Basel). 2022;14(18):4388.PubMed
10.
go back to reference Gu J, Zhang B, An R, et al. Molecular interactions of the long noncoding RNA NEAT1 in cancer. Cancers (Basel). 2022;14(16):4009.PubMed Gu J, Zhang B, An R, et al. Molecular interactions of the long noncoding RNA NEAT1 in cancer. Cancers (Basel). 2022;14(16):4009.PubMed
11.
go back to reference Knutsen E, Harris AL, Perander M. Expression and functions of long non-coding RNA NEAT1 and isoforms in breast cancer. Br J Cancer. 2022;126(4):551–61.PubMed Knutsen E, Harris AL, Perander M. Expression and functions of long non-coding RNA NEAT1 and isoforms in breast cancer. Br J Cancer. 2022;126(4):551–61.PubMed
12.
go back to reference Azizidoost S, Ghaedrahmati F, Anbiyaee O, Ahmad Ali R, Cheraghzadeh M, Farzaneh M. Emerging roles for lncRNA-NEAT1 in colorectal cancer. Cancer Cell Int. 2022;22(1):209.PubMedCentralPubMed Azizidoost S, Ghaedrahmati F, Anbiyaee O, Ahmad Ali R, Cheraghzadeh M, Farzaneh M. Emerging roles for lncRNA-NEAT1 in colorectal cancer. Cancer Cell Int. 2022;22(1):209.PubMedCentralPubMed
13.
go back to reference Li K, Wang Z. lncRNA NEAT1: Key player in neurodegenerative diseases. Ageing Res Rev. 2023;86: 101878.PubMed Li K, Wang Z. lncRNA NEAT1: Key player in neurodegenerative diseases. Ageing Res Rev. 2023;86: 101878.PubMed
14.
go back to reference Zhang A, Qian F, Li Y, et al. Research progress of metformin in the treatment of liver fibrosis. Int Immunopharmacol. 2023;116: 109738.PubMed Zhang A, Qian F, Li Y, et al. Research progress of metformin in the treatment of liver fibrosis. Int Immunopharmacol. 2023;116: 109738.PubMed
15.
go back to reference Nokkeaw A, Thamjamrassri P, Tangkijvanich P, Ariyachet C. Regulatory functions and mechanisms of circular RNAs in hepatic stellate cell activation and liver fibrosis. Cells. 2023;12(3):378.PubMedCentralPubMed Nokkeaw A, Thamjamrassri P, Tangkijvanich P, Ariyachet C. Regulatory functions and mechanisms of circular RNAs in hepatic stellate cell activation and liver fibrosis. Cells. 2023;12(3):378.PubMedCentralPubMed
16.
go back to reference Yu F, Jiang Z, Chen B, Dong P, Zheng J. NEAT1 accelerates the progression of liver fibrosis via regulation of microRNA-122 and Kruppel-like factor 6. J Mol Med (Berl). 2017;95(11):1191–202.PubMed Yu F, Jiang Z, Chen B, Dong P, Zheng J. NEAT1 accelerates the progression of liver fibrosis via regulation of microRNA-122 and Kruppel-like factor 6. J Mol Med (Berl). 2017;95(11):1191–202.PubMed
17.
go back to reference Kong Y, Huang T, Zhang H, et al. The lncRNA NEAT1/miR-29b/Atg9a axis regulates IGFBPrP1-induced autophagy and activation of mouse hepatic stellate cells. Life Sci. 2019;237: 116902.PubMed Kong Y, Huang T, Zhang H, et al. The lncRNA NEAT1/miR-29b/Atg9a axis regulates IGFBPrP1-induced autophagy and activation of mouse hepatic stellate cells. Life Sci. 2019;237: 116902.PubMed
18.
go back to reference Jin SS, Lin XF, Zheng JZ, Wang Q, Guan HQ. lncRNA NEAT1 regulates fibrosis and inflammatory response induced by nonalcoholic fatty liver by regulating miR-506/GLI3. Eur Cytokine Netw. 2019;30(3):98–106.PubMed Jin SS, Lin XF, Zheng JZ, Wang Q, Guan HQ. lncRNA NEAT1 regulates fibrosis and inflammatory response induced by nonalcoholic fatty liver by regulating miR-506/GLI3. Eur Cytokine Netw. 2019;30(3):98–106.PubMed
19.
go back to reference Zhang Z, Wen H, Peng B, Weng J, Zeng F. Downregulated microRNA-129-5p by long non-coding RNA NEAT1 upregulates PEG3 expression to aggravate non-alcoholic steatohepatitis. Front Genet. 2021;11: 563265.PubMedCentralPubMed Zhang Z, Wen H, Peng B, Weng J, Zeng F. Downregulated microRNA-129-5p by long non-coding RNA NEAT1 upregulates PEG3 expression to aggravate non-alcoholic steatohepatitis. Front Genet. 2021;11: 563265.PubMedCentralPubMed
20.
go back to reference Ye J, Lin Y, Yu Y, Sun D. LncRNA NEAT1/microRNA-129-5p/SOCS2 axis regulates liver fibrosis in alcoholic steatohepatitis. J Transl Med. 2020;18(1):445.PubMedCentralPubMed Ye J, Lin Y, Yu Y, Sun D. LncRNA NEAT1/microRNA-129-5p/SOCS2 axis regulates liver fibrosis in alcoholic steatohepatitis. J Transl Med. 2020;18(1):445.PubMedCentralPubMed
21.
go back to reference Huang W, Huang F, Zhang R, Luo H. LncRNA Neat1 expedites the progression of liver fibrosis in mice through targeting miR-148a-3p and miR-22-3p to upregulate Cyth3. Cell Cycle. 2021;20(5–6):490–507.PubMedCentralPubMed Huang W, Huang F, Zhang R, Luo H. LncRNA Neat1 expedites the progression of liver fibrosis in mice through targeting miR-148a-3p and miR-22-3p to upregulate Cyth3. Cell Cycle. 2021;20(5–6):490–507.PubMedCentralPubMed
22.
go back to reference Wang Q, Wei S, Li L, et al. miR-139-5p sponged by LncRNA NEAT1 regulates liver fibrosis via targeting β-catenin/SOX9/TGF-β1 pathway. Cell Death Discov. 2021;7(1):243.PubMedCentralPubMed Wang Q, Wei S, Li L, et al. miR-139-5p sponged by LncRNA NEAT1 regulates liver fibrosis via targeting β-catenin/SOX9/TGF-β1 pathway. Cell Death Discov. 2021;7(1):243.PubMedCentralPubMed
23.
go back to reference Shu B, Zhang RZ, Zhou YX, He C, Yang X. METTL3-mediated macrophage exosomal NEAT1 contributes to hepatic fibrosis progression through Sp1/TGF-β1/Smad signaling pathway. Cell Death Discov. 2022;8(1):266.PubMedCentralPubMed Shu B, Zhang RZ, Zhou YX, He C, Yang X. METTL3-mediated macrophage exosomal NEAT1 contributes to hepatic fibrosis progression through Sp1/TGF-β1/Smad signaling pathway. Cell Death Discov. 2022;8(1):266.PubMedCentralPubMed
24.
go back to reference Lu Y, Zhang R, Gu X, Wang X, Xi P, Chen X. Exosomes from tubular epithelial cells undergoing epithelial-to-mesenchymal transition promote renal fibrosis by M1 macrophage activation. FASEB Bioadv. 2023;5(3):101–13.PubMedCentralPubMed Lu Y, Zhang R, Gu X, Wang X, Xi P, Chen X. Exosomes from tubular epithelial cells undergoing epithelial-to-mesenchymal transition promote renal fibrosis by M1 macrophage activation. FASEB Bioadv. 2023;5(3):101–13.PubMedCentralPubMed
25.
go back to reference Kim IY, Song SH, Seong EY, Lee DW, Bae SS, Lee SB. Akt1 is involved in renal fibrosis and tubular apoptosis in a murine model of acute kidney injury-to-chronic kidney disease transition. Exp Cell Res. 2023;424(2): 113509.PubMed Kim IY, Song SH, Seong EY, Lee DW, Bae SS, Lee SB. Akt1 is involved in renal fibrosis and tubular apoptosis in a murine model of acute kidney injury-to-chronic kidney disease transition. Exp Cell Res. 2023;424(2): 113509.PubMed
26.
go back to reference Huang S, Xu Y, Ge X, et al. Long noncoding RNA NEAT1 accelerates the proliferation and fibrosis in diabetic nephropathy through activating Akt/mTOR signaling pathway. J Cell Physiol. 2019;234(7):11200–7.PubMed Huang S, Xu Y, Ge X, et al. Long noncoding RNA NEAT1 accelerates the proliferation and fibrosis in diabetic nephropathy through activating Akt/mTOR signaling pathway. J Cell Physiol. 2019;234(7):11200–7.PubMed
27.
go back to reference Yang YL, Xue M, Jia YJ, et al. Long noncoding RNA NEAT1 is involved in the protective effect of Klotho on renal tubular epithelial cells in diabetic kidney disease through the ERK1/2 signaling pathway. Exp Mol Med. 2020;52(2):266–80.PubMedCentralPubMed Yang YL, Xue M, Jia YJ, et al. Long noncoding RNA NEAT1 is involved in the protective effect of Klotho on renal tubular epithelial cells in diabetic kidney disease through the ERK1/2 signaling pathway. Exp Mol Med. 2020;52(2):266–80.PubMedCentralPubMed
28.
go back to reference Li N, Jia T, Li YR. LncRNA NEAT1 accelerates the occurrence and development of diabetic nephropathy by sponging miR-23c. Eur Rev Med Pharmacol Sci. 2020;24(3):1325–37.PubMed Li N, Jia T, Li YR. LncRNA NEAT1 accelerates the occurrence and development of diabetic nephropathy by sponging miR-23c. Eur Rev Med Pharmacol Sci. 2020;24(3):1325–37.PubMed
29.
go back to reference Li C, Liu YF, Huang C, Chen YX, Xu CY, Chen Y. Long noncoding RNA NEAT1 sponges miR-129 to modulate renal fibrosis by regulation of collagen type I. Am J Physiol Renal Physiol. 2020;319(1):F93–105.PubMed Li C, Liu YF, Huang C, Chen YX, Xu CY, Chen Y. Long noncoding RNA NEAT1 sponges miR-129 to modulate renal fibrosis by regulation of collagen type I. Am J Physiol Renal Physiol. 2020;319(1):F93–105.PubMed
30.
go back to reference Ma T, Li H, Liu H, et al. Neat1 promotes acute kidney injury to chronic kidney disease by facilitating tubular epithelial cells apoptosis via sequestering miR-129-5p. Mol Ther. 2022;30(10):3313–32.PubMedCentralPubMed Ma T, Li H, Liu H, et al. Neat1 promotes acute kidney injury to chronic kidney disease by facilitating tubular epithelial cells apoptosis via sequestering miR-129-5p. Mol Ther. 2022;30(10):3313–32.PubMedCentralPubMed
31.
go back to reference Chen Y, Huang C, Duan ZB, Chen YX, Xu CY. LncRNA NEAT1 accelerates renal fibrosis progression via targeting miR-31 and modulating RhoA/ROCK signal pathway. Am J Physiol Cell Physiol. 2023;324(2):C292–306.PubMed Chen Y, Huang C, Duan ZB, Chen YX, Xu CY. LncRNA NEAT1 accelerates renal fibrosis progression via targeting miR-31 and modulating RhoA/ROCK signal pathway. Am J Physiol Cell Physiol. 2023;324(2):C292–306.PubMed
32.
go back to reference McKinsey TA, Foo R, Anene-Nzelu CG, et al. Emerging epigenetic therapies of cardiac fibrosis and remodelling in heart failure: from basic mechanisms to early clinical development. Cardiovasc Res. 2023;118(18):3482–98.PubMed McKinsey TA, Foo R, Anene-Nzelu CG, et al. Emerging epigenetic therapies of cardiac fibrosis and remodelling in heart failure: from basic mechanisms to early clinical development. Cardiovasc Res. 2023;118(18):3482–98.PubMed
33.
go back to reference de Oliveira CR, Abual’anaz B, Rattan SG, Filomeno K, Dixon IMC. Novel factors that activate and deactivate cardiac fibroblasts: a new perspective for treatment of cardiac fibrosis. Wound Repair Regen. 2021;29(4):667–77. de Oliveira CR, Abual’anaz B, Rattan SG, Filomeno K, Dixon IMC. Novel factors that activate and deactivate cardiac fibroblasts: a new perspective for treatment of cardiac fibrosis. Wound Repair Regen. 2021;29(4):667–77.
34.
go back to reference Raziyeva K, Kim Y, Zharkinbekov Z, Temirkhanova K, Saparov A. Novel therapies for the treatment of cardiac fibrosis following myocardial infarction. Biomedicines. 2022;10(9):2178.PubMedCentralPubMed Raziyeva K, Kim Y, Zharkinbekov Z, Temirkhanova K, Saparov A. Novel therapies for the treatment of cardiac fibrosis following myocardial infarction. Biomedicines. 2022;10(9):2178.PubMedCentralPubMed
35.
go back to reference Kesherwani V, Shahshahan HR, Mishra PK. Cardiac transcriptome profiling of diabetic Akita mice using microarray and next generation sequencing. PLoS ONE. 2017;12(8): e0182828.PubMedCentralPubMed Kesherwani V, Shahshahan HR, Mishra PK. Cardiac transcriptome profiling of diabetic Akita mice using microarray and next generation sequencing. PLoS ONE. 2017;12(8): e0182828.PubMedCentralPubMed
36.
go back to reference Kenneweg F, Bang C, Xiao K, et al. Long noncoding RNA-enriched vesicles secreted by hypoxic cardiomyocytes drive cardiac fibrosis. Mol Ther Nucleic Acids. 2019;18:363–74.PubMedCentralPubMed Kenneweg F, Bang C, Xiao K, et al. Long noncoding RNA-enriched vesicles secreted by hypoxic cardiomyocytes drive cardiac fibrosis. Mol Ther Nucleic Acids. 2019;18:363–74.PubMedCentralPubMed
37.
go back to reference Dai H, Zhao N, Liu H, Zheng Y, Zhao L. LncRNA nuclear-enriched abundant transcript 1 regulates atrial fibrosis via the miR-320/NPAS2 axis in atrial fibrillation. Front Pharmacol. 2021;12: 647124.PubMedCentralPubMed Dai H, Zhao N, Liu H, Zheng Y, Zhao L. LncRNA nuclear-enriched abundant transcript 1 regulates atrial fibrosis via the miR-320/NPAS2 axis in atrial fibrillation. Front Pharmacol. 2021;12: 647124.PubMedCentralPubMed
38.
go back to reference Ge Z, Yin C, Li Y, et al. Long noncoding RNA NEAT1 promotes cardiac fibrosis in heart failure through increased recruitment of EZH2 to the Smad7 promoter region. J Transl Med. 2022;20(1):7.PubMedCentralPubMed Ge Z, Yin C, Li Y, et al. Long noncoding RNA NEAT1 promotes cardiac fibrosis in heart failure through increased recruitment of EZH2 to the Smad7 promoter region. J Transl Med. 2022;20(1):7.PubMedCentralPubMed
39.
go back to reference Ding JF, Zhou Y, Xu SS, et al. Epigenetic control of LncRNA NEAT1 enables cardiac fibroblast pyroptosis and cardiac fibrosis. Eur J Pharmacol. 2023;938: 175398.PubMed Ding JF, Zhou Y, Xu SS, et al. Epigenetic control of LncRNA NEAT1 enables cardiac fibroblast pyroptosis and cardiac fibrosis. Eur J Pharmacol. 2023;938: 175398.PubMed
40.
go back to reference Ortiz-Zapater E, Signes-Costa J, Montero P, Roger I. Lung fibrosis and fibrosis in the lungs: Is it all about myofibroblasts? Biomedicines. 2022;10(6):1423.PubMedCentralPubMed Ortiz-Zapater E, Signes-Costa J, Montero P, Roger I. Lung fibrosis and fibrosis in the lungs: Is it all about myofibroblasts? Biomedicines. 2022;10(6):1423.PubMedCentralPubMed
41.
go back to reference Fukushima K, Satoh T, Kida H, Kumanogoh A. Revisiting cell death responses in fibrotic lung disease: crosstalk between structured and non-structured cells. Diagnostics (Basel). 2020;10(7):504.PubMed Fukushima K, Satoh T, Kida H, Kumanogoh A. Revisiting cell death responses in fibrotic lung disease: crosstalk between structured and non-structured cells. Diagnostics (Basel). 2020;10(7):504.PubMed
42.
go back to reference Calthorpe RJ, Poulter C, Smyth AR, et al. Complex roles of TGF-β signaling pathways in lung development and bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol. 2023;324(3):L285–96.PubMedCentralPubMed Calthorpe RJ, Poulter C, Smyth AR, et al. Complex roles of TGF-β signaling pathways in lung development and bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol. 2023;324(3):L285–96.PubMedCentralPubMed
43.
go back to reference Fukushima K, Satoh T, Sugihara F, et al. Dysregulated expression of the nuclear exosome targeting complex component Rbm7 in nonhematopoietic cells licenses the development of fibrosis. Immunity. 2020;52(3):542-556.e13.PubMed Fukushima K, Satoh T, Sugihara F, et al. Dysregulated expression of the nuclear exosome targeting complex component Rbm7 in nonhematopoietic cells licenses the development of fibrosis. Immunity. 2020;52(3):542-556.e13.PubMed
44.
go back to reference Zhang Y, Yao XH, Wu Y, Cao GK, Han D. LncRNA NEAT1 regulates pulmonary fibrosis through miR-9–5p and TGF-β signaling pathway. Eur Rev Med Pharmacol Sci.;24(16):8483–8492. Zhang Y, Yao XH, Wu Y, Cao GK, Han D. LncRNA NEAT1 regulates pulmonary fibrosis through miR-9–5p and TGF-β signaling pathway. Eur Rev Med Pharmacol Sci.;24(16):8483–8492.
45.
go back to reference Liu Y, Lu FA, Wang L, Wang YF, Wu CF. Long non‑coding RNA NEAT1 promotes pulmonary fibrosis by regulating the microRNA‑455‑3p/SMAD3 axis. Mol Med Rep.;23(3):218. Liu Y, Lu FA, Wang L, Wang YF, Wu CF. Long non‑coding RNA NEAT1 promotes pulmonary fibrosis by regulating the microRNA‑455‑3p/SMAD3 axis. Mol Med Rep.;23(3):218.
46.
go back to reference Zhang X, Duan XJ, Li LR, Chen YP. lncRNA NEAT1 promotes hypoxia-induced inflammation and fibrosis of alveolar epithelial cells via targeting miR-29a/NFATc3 axis. Kaohsiung J Med Sci.;38(8):739–748. Zhang X, Duan XJ, Li LR, Chen YP. lncRNA NEAT1 promotes hypoxia-induced inflammation and fibrosis of alveolar epithelial cells via targeting miR-29a/NFATc3 axis. Kaohsiung J Med Sci.;38(8):739–748.
47.
go back to reference Ghafouri-Fard S, Abak A, Talebi SF, et al. Role of miRNA and lncRNAs in organ fibrosis and aging. Biomed Pharmacother. 2021;143:112132. Ghafouri-Fard S, Abak A, Talebi SF, et al. Role of miRNA and lncRNAs in organ fibrosis and aging. Biomed Pharmacother. 2021;143:112132.
48.
go back to reference Di Mauro S, Scamporrino A, Fruciano M, et al. Circulating coding and long non-coding RNAs as potential biomarkers of idiopathic pulmonary fibrosis. Int J Mol Sci. 2020;21(22):8812.PubMedCentralPubMed Di Mauro S, Scamporrino A, Fruciano M, et al. Circulating coding and long non-coding RNAs as potential biomarkers of idiopathic pulmonary fibrosis. Int J Mol Sci. 2020;21(22):8812.PubMedCentralPubMed
Metadata
Title
The mechanisms and therapeutic potential of long noncoding RNA NEAT1 in fibrosis
Author
Xiaoying Jiang
Publication date
22-09-2023
Publisher
Springer International Publishing
Published in
Clinical and Experimental Medicine / Issue 7/2023
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-023-01191-1

Other articles of this Issue 7/2023

Clinical and Experimental Medicine 7/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare